The American Journal of Psychiatry published a new study that suggests cannabidiol (CBD) can safely help patients with schizophrenia. In the double-blind trial, 43 schizophrenia patients received 1000mg of CBD a day for six weeks, while another 45 received a placebo. Both groups, which continued to take their existing antipsychotic medication, had their disorders assessed before and after the trial.
How did the 43 patients respond to the cannabis compound?
"Compared with the placebo group, the CBD group had lower levels of positive psychotic symptoms and were more likely to have been rated as improved and as not severely unwell by the treating clinician," the study stated. "Patients who received CBD also showed greater improvements that fell short of statistical significance in cognitive performance and in overall functioning. CBD was well tolerated, and rates of adverse events were similar between the CBD and placebo groups."
The researchers ultimately concluded that CBD "may represent a new class of treatment for the disorder."
The irony, of course, is that bureaucrats claimed cannabis turned people into crazy killers, which helped them institute cannabis prohibition in 1937. In the last several decades, modern prohibitionists repackaged the madness claim in clinical speak, i.e., cannabis can cause psychosis and schizophrenia. The Food and Drug Administration (FDA) refuted this claim in 2016, and the present study suggests cannabis might actually play a role in treating the disorders.